Although three million deaths is a huge number, the cost of the pandemic in terms of human lives is much greater. Its impact on non COVID-19 patients who fell ill or needing emergency care in the middle of a pandemic is dramatic.
Tekcapital plc Announces Full Fiscal Year 2020 Financial Results for the Year-Ended November 30, 2020 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Housing and Development Newsletter
Dr. Michael Kearney, VNA Health’s Palliative Care associate medical director, has been at the forefront of our local Palliative Care movement in Santa Barbara County.
“Palliative Care is focused on what the patient’s needs are,” shares Dr. Kearney. “Yes, the diagnosis or prognosis is important, but that is not our focus. It is about helping the patient feel better, to manage their physical and non-physical symptoms. If they feel well physically, psychologically and spiritually, then their quality of life improves.”
Dr. Kearney’s first experience with palliative care and hospice care was as a medical student in the 1970s.
Oxygen Concentrators in Huge Demand During COVID Second Wave Apr 29, 2021, 11:43 IST
Amidst a rise in the number of cases in the second wave of coronavirus, patients are suffering from oxygen and antiviral drug shortage. Now, there is a huge demand for oxygen concentrators and oxygen cylinders. The oxygen concentrators are devices that concentrate the oxygen from ambient air and it is recommended by doctors so that the shortage of oxygen in a person s body is fulfilled.
Oxygen tanks or cylinders were common items used to provide oxygen assistance to patients prior to the Covid-19 pandemic. However, the demand for the relatively new technology of oxygen concentrators has increased due to a shortage of such cylinders, which can only accommodate a small amount of medical oxygen and later it has to be refilled.
Published: Apr 23, 2021
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE)
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to standard of care was observed in the trial. One patient death was reported in the ensifentrine treatment group.
“Overall, the patients in this study recovered exceptionally well, as the mortality rate in the study was much lower than aggregate data from the hospital would have suggested over the same time period,” commented Mike Wells, MD, a pulmonologist and Principal Investigator at the